Ribbon herpes vaccine! GlaxoSmithKline (Shingrix) is officially available in China for the prevention of shingles in adults aged 50!

, July 02, 2020 /PRNewswire/ -- GlaxoSmithKline (GSK) has announced that shingrix, a shingles vaccine, is officially on the market in China for the prevention of shingles in adults aged 50 and overShingrix is a recombinant subunit adjastorative vaccine, divided into two doses of muscle injectionThe product is one of the first batch of 48 overseas listed "clinically urgently needed new drugs", and is currently the only domestic marketed recombinant shingles vaccine, effectively filling the gap in the field of herpes disease prevention in China, and further expanding China's vaccine prevention systemshingles is caused by the reactivation of the chickenpox-shingherpes virusAlmost all adults aged 50 and over have been infected with the chickenpox-shingherpes virus and may reactivate with ageaccording to statistics, China's 50 years of age and older people each year new cases of shingles about 1.56 millionWith China's accelerated entry into the aging society, the burden of shingles disease in China is becoming more and more seriousThe Outline of the "Healthy China 2030" Plan regards healthy aging as an important strategic goal and promotes a series of health promotion actions for the elderlyAt the same time, China also proposed to build a strong public health system, emphasizing the importance of vaccines for the health of the peopleShingrix uses chickenpox-striped herpes virus glycoprotein E (gE) and patented adjectoother system AS01B to produce a strong and long-lasting immune responseIn clinical trials in 18 countries and regions around the world, Xin's evidence showed up to 90% of the protective effects of shingles, effectively reducing the risk of shingles in people 50 years and olderherpes zoster; picture: medicalnewstoday.com
DrThomas Breuer, GSK's Senior Vice President and Chief Medical Officer, said, "Xin's islikea can help people overcome the decreased immune function that comes with ageIt is great to see this innovative vaccine available in China, helping the public reduce the burden of this painful diseaseQi Xin, vice president of gSKand general manager of prescription drugs and vaccines in China, said: "The rapid approval of Xin'an Lishi to the market fully reflects the importance china attaches to important new prevention and treatment programs." I believe that the arrival of Xin'an Lishi will help to raise the awareness of adult vaccination in our country, better meet the challenges of disease, and thus improve the health literacy of the whole population As the world's leading vaccine company, GlaxoSmithKline will always uphold the concept of 'doing more, feeling more comfortable and living longer', so that more innovative vaccines come to China faster and faster, and actively work with partners to help the development of China's immunization industry and contribute to the construction of 'Healthy China 2030' " (BioValleyBioon.com) original source: GlaxoSmithKline